Free Trial

Zai Lab (ZLAB) Stock Price, News & Analysis

$21.57
+1.27 (+6.26%)
(As of 09/11/2024 ET)
Today's Range
$20.15
$21.69
50-Day Range
$16.25
$20.30
52-Week Range
$13.48
$31.22
Volume
1.02 million shs
Average Volume
626,687 shs
Market Capitalization
$2.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.97

Zai Lab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
173.4% Upside
$58.97 Price Target
Short Interest
Bearish
4.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.67mentions of Zai Lab in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$975,291 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.95) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

500th out of 911 stocks

Pharmaceutical Preparations Industry

227th out of 423 stocks

ZLAB stock logo

About Zai Lab Stock (NASDAQ:ZLAB)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock Price History

ZLAB Stock News Headlines

How you could collect “AI Royalties” from NVIDIA, META and TSMC...
If you've missed out on the first wave of big AI winners... Don't worry. Because there's a much better - and potentially much more lucrative way - to play the $5 Trillion AI boom.
ZLAB Sep 2024 17.500 put
Invest before this deal closes on 9/18
This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.
What Wall Street expects from Zai Lab's earnings
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2024
Today
9/12/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZLAB
Employees
2,175
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.97
High Stock Price Target
$73.34
Low Stock Price Target
$38.00
Potential Upside/Downside
+173.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-334,620,000.00
Pretax Margin
-92.44%

Debt

Sales & Book Value

Annual Sales
$266.72 million
Book Value
$8.05 per share

Miscellaneous

Free Float
94,399,000
Market Cap
$2.15 billion
Optionable
Optionable
Beta
1.07
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


ZLAB Stock Analysis - Frequently Asked Questions

How have ZLAB shares performed this year?

Zai Lab's stock was trading at $27.33 at the start of the year. Since then, ZLAB shares have decreased by 21.1% and is now trading at $21.57.
View the best growth stocks for 2024 here
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.16. The firm earned $100.50 million during the quarter, compared to analysts' expectations of $94.46 million. Zai Lab had a negative trailing twelve-month return on equity of 37.96% and a negative net margin of 92.44%.

When did Zai Lab IPO?

Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Who are Zai Lab's major shareholders?

Top institutional shareholders of Zai Lab include Clearbridge Investments LLC (0.80%), M&G Plc (0.44%), Candriam S.C.A. (0.37%) and TD Asset Management Inc (0.22%). Insiders that own company stock include Ying Du, Harald Reinhart, William Lis, Joshua L Smiley, Frazor Titus Edmondson III, Yajing Chen, Peter Wirth, Tao Fu and John D Diekman.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI) and Marvell Technology (MRVL).

This page (NASDAQ:ZLAB) was last updated on 9/12/2024 by MarketBeat.com Staff

From Our Partners